Ngabe amaphilisi e-Alli Diet (Orlistat) ayasebenza? Ukubuyekezwa Okusekelwe Ebufakazini

-Delile

• Yini i-Alli (Orlistat)?
• Usebenza kanjani u-Alli?
• I-Alli Ingakusiza Ukwehlisa Amanani Amancane Esisindo
• Izifundo ezengeziwe
• Ngabe amaphilisi e-Alli Diet Anazo Ezinye Izinzuzo Zezempilo?
• Imiphumela emibi, Isikali nokuthi Ungayisebenzisa Kanjani
• Ingabe Kufanele Uzame u-Alli?

Ukwehla kwesisindo kungaba nzima kakhulu.

Olunye ucwaningo lukhombisa ukuthi abantu abangama-85% bayehluleka ukusebenzisa izindlela ezijwayelekile zokwehlisa isisindo (1).

Lokhu kudala ukuthi abantu abaningi bafune ezinye izindlela, njengamaphilisi okudla, ukuze bathole usizo.

I-Alli yiphilisi elilodwa lokudla okunjalo, kepha isidakamizwa esisebenzisa imithi kunesengezo esisekelwe ezitshalweni.

Lo muthi ulinganisela inani lamafutha adlayo imizimba yethu emunca, enciphisa ukungeniswa kwekhalori futhi iholele ekunciphiseni isisindo.

Lokhu ukubuyekezwa okuningiliziwe kwamaphilisi okudla e-Alli: ayini, asebenza kanjani, nokuthi akulungele yini.

Yini i-Alli (Orlistat)?

I-Alli inguqulo ye-counter-the-counter yomuthi wokulahlekelwa isisindo wemithi obizwa nge-orlistat.

Uhlobo lwe-prescription-only lubizwa nge-Xenical, oluqukethe isilinganiso esiphezulu. Amaphilisi okudla e-Alli aqukethe ama-60 mg we-orlistat, kanti amaphilisi e-Xenical aqukethe i-120 mg.

Lesi sidakamizwa savunywa okokuqala yi-FDA ngo-1999. Imvamisa inikezwa ukuphathwa kokukhuluphala kwesikhathi eside, kanye nokudla okunamafutha aphansi, okunomkhawulo wekhalori.

I-Alli inguqulo ye-orlistat e-over-the-counter, umuthi owenza imithi osetshenziselwa ukuphatha ukukhuluphala. Iphinde itholakale ngomuthi kadokotela njengeXenical.

Usebenza kanjani u-Alli?

U-Alli usebenza ngokuvimbela umzimba ekumunceni amafutha adlayo.

Ngokuqondile, ivimba i-enzyme esiswini ebizwa nge-lipase.

ILipase ibalulekile ekugayweni kwamafutha esiwadlayo. Kuyasiza ukwehlukanisa amafutha abe ngama-acid anamafutha angacoshwa ngumzimba.

Ngaphandle kwale enzyme, amafutha adlayo adlula ukugayeka kokudla bese ekhishwa emzimbeni.

Njenge-lipase-inhibitor, u-Alli ukhonjisiwe ukunciphisa ukumuncwa kwamafutha adlayo cishe ngama-30% ().

Ngoba amafutha ekudleni anama-calories amaningi, lokhu kuholela ekutheni amakhalori ambalwa acutshungulwe ngumzimba, okungaholela ekwehliseni isisindo.

U-Alli uphazamisa ukugaywa kwamafutha okudla futhi uvimba cishe u-30% wamafutha ukuthi angangeni. Lokhu kuholela ekwehlisweni okuphelele kokudla kwekhalori.

I-Alli Ingakusiza Ukwehlisa Amanani Amancane Esisindo

Izifundo eziningi zabantu ezinkulu zenziwe ku-orlistat, isakhi esisebenzayo kumaphilisi okudla e-Alli.

Okudume kakhulu isifundo se-Swedish XENDOS, ebifaka abantu abakhuluphele ngokweqile abangama-3,305 futhi yathatha iminyaka engu-4 (3).

Kwakunamaqembu amabili ocwaningweni. Omunye uthathe i-120 mg ye-orlistat, kathathu nsuku zonke, ngenkathi elinye iqembu lithatha i-placebo.

Bonke ababambiqhaza bayalelwe ukuthi badle ama-calories ambalwa angama-800 ngosuku, futhi bakhawulele amafutha okudla abe ngu-30% wama-calories. Baphinde bakhuthazwa ukuthi bahambehambe nsuku zonke.

Le grafu ikhombisa ushintsho lwesisindo emaqenjini amabili ngaphezu kweminyaka engu-4 (3):

Ngonyaka wokuqala, ukwehla kwesisindo okujwayelekile eqenjini eliphethwe i-orlistat kwakungamakhilogremu angama-23.3 (10.6 kg), kanti iqembu le-placebo lalahlekelwa amakhilogremu angu-13.6 kuphela.

Njengoba kukhonjisiwe kugrafu, kube nokutholakala kwesisindo okuphawulekayo kuwo womabili amaqembu eminyakeni emi-3 esele. Iziguli ezelashwa nge-Orlistat zigcine sezilahle amakhilogremu ayi-12.8 (5.8 kg), uma kuqhathaniswa namakhilogremu ayi-6.6 (3.0 kg) kulabo abathola i-placebo.

Ngokwalolu cwaningo, i-orlistat ehlangene nokudla kanye nokuvivinya umzimba kungenza ulahlekelwe isisindo esiphindwe kabili kunokudla nokuzivocavoca wedwa.

Izifundo ezengeziwe

Ngokuya ngocwaningo lokubuyekeza, isilinganiso esilahlekile sezinyanga eziyi-12 sabantu abadala abathatha i-orlistat cishe singama-7.5 lbs (3.4 kg) amakhulu kune-placebo ().

Lokhu kufinyelela ku-3.1% wesisindo sokuqala, okungamangalisi kangako. Kubuye kubonakale ukuthi isisindo sitholwa kancane ngemuva konyaka wokuqala wokwelashwa.

Kuyathakazelisa ukuthi olunye ucwaningo lukhombisile ukuthi ukudla okungenazidakamizwa okunama-carb kwakusebenza kahle njengakho konke i-orlistat kanye nokudla okunamafutha aphansi kuhlangene ().

I-Alli / orlistat isidakamizwa esisebenza kahle sokulwa nokukhuluphala, ngokuncipha kwesisindo ezinyangeni eziyi-12 kungu-3.4 kg (7.5 lbs) omkhulu kune-placebo.

Ngabe amaphilisi e-Alli Diet Anazo Ezinye Izinzuzo Zezempilo?

U-Alli uphinde waxhunyaniswa nezinye izinzuzo zezempilo, mhlawumbe ngenxa yemiphumela yokuncipha kwesisindo.

• Ukwehlisa ubungozi besifo sikashukela sohlobo 2: Esifundweni se-XENDOS, ukusetshenziswa kweminyaka eyi-4 kwe-orlistat kunciphise ubungozi bokuthola uhlobo lwesifo sikashukela sohlobo lwe-2 ngo-37% (3).
• Ukwehlisa umfutho wegazi: Ucwaningo lukhombisa ukuthi i-Alli ingaholela ekunciphiseni okuncane komfutho wegazi (,).
• Inani eliphelele- ne-LDL-cholesterol: Ucwaningo lukhombisa ukuthi u-Alli angathonya amazinga we-cholesterol (,).

Ukusetshenziswa isikhathi eside kuka-Alli kunganciphisa ubungozi bohlobo lwesifo sikashukela sohlobo lwesibili futhi kusize ukuvikela ezifweni zenhliziyo.

Imiphumela emibi, Isikali nokuthi Ungayisebenzisa Kanjani

Amaphilisi okudla i-Alli anemiphumela engezansi ebhalwe kahle okufanele uyiqaphele ().

Njengoba zivimba ukumuncwa kwamafutha, ukutholakala kwamafutha angadliwe emathunjini kungadala izimpawu zokugaya ukudla, njengobuhlungu besisu, isifo sohudo kanye nokuqunjelwa.

Abanye abantu futhi babhekana nokungazibambi kwezindle nokuzikhulula, izitulo ezinamafutha.

Ukusetshenziswa okuqhubekayo kwe-Alli futhi kungaphazamisa ukumuncwa kwezakhi ezincibilika njengamavithamini A, D, E noK.

Ngalesi sizathu, kunconywa ukuthatha i-multivitamin kanye nokwelashwa.

I-Alli nayo ingaphazamisa ukumuncwa kwemithi ethile, futhi kubikwe amacala ambalwa okwehluleka kwesibindi kanye nobuthi bezinso.

Abantu abadla imishanguzo noma abanesimo esithile sezempilo kufanele babonane nodokotela wabo ngaphambi kokuphuza amaphilisi okudla i-Alli.

Ngokuya ngemininingwane yesikhathi eside enomkhawulo etholakalayo, imihlahlandlela eminingi yemitholampilo incoma ukuthi i-Alli ayisetshenziswa ngokuqhubekayo isikhathi esingaphezu kwezinyanga ezingama-24.

Isilinganiso esifanelekile esisetshenziswe ezifundweni singu-120 mg, kathathu ngosuku.

Amaphilisi okudla i-Alli anemiphumela emibi eminingi. Zingadala izinkinga zokugaya ukudla nokushoda kwezakhi, futhi zingaphazamisa nemithi ethile. Umthamo ofundwe kahle kakhulu ngu-120 mg, kathathu ngosuku.

Ingabe Kufanele Uzame u-Alli?

Amaphilisi okudla i-Alli aphakathi kwezinsizakusebenza ezimbalwa zokwehlisa isisindo empeleni ezisebenza ngezinga elithile. Kodwa-ke, imiphumela ayimangalisi njengoba abantu abaningi bengathanda.

Okungcono kakhulu, ukuthi ungakwazi ukulahla isisindo esithe xaxa, kepha kuphela lapho kuhlangene ngokudla kwesisindo nokuvivinya umzimba.

Ngokwengeziwe, imiphumela ezuzisayo ekulahlekelweni kwesisindo idinga ukukalwa ngemiphumela emibi yezinkinga zokugaya ukudla kanye nokushoda okungenzeka kube nomsoco.

Ukungasho, udinga futhi ukudla ukudla okunomkhawulo wekhalori, okunamafutha aphansi, okungabajabulisi kakhulu abantu abaningi.

Uma ufuna ukwehlisa isisindo futhi yigcine, bese ukudla amaprotheni amaningi kanye nama-carbs ambalwa kuyindlela ephumelela kakhulu futhi esimeme.